• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Silo Pharma Inc.

    9/5/25 5:09:03 PM ET
    $SILO
    Apparel
    Consumer Discretionary
    Get the next $SILO alert in real time by email
    DEFA14A 1 ea0256234-defa14a_silopharma.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Material under § 240.14a-12

     

    SILO PHARMA, INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     

     

     

    Your Vote Counts! SILO PHARMA, INC. 677 N. WASHINGTON BLVD SARASOTA, FL 34236 SILO PHARMA, INC. 2025 Annual Meeting Vote by October 23, 2025 11:59 PM ET Vote in Person at the Meeting* October 24, 2025 11:00 a.m. Eastern Time 677 N. Washington Boulevard Sarasota, Florida 34236 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V79048 - P36823 You invested in SILO PHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on October 24, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10 - K online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 10, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V79049 - P36823 For 1. Election of the following four (4) director nominees to hold office until the 2026 Annual Meeting. Nominees: 1) ERIC WEISBLUM 2) WAYNE D. LINSLEY 3) DR. KEVIN MUÑOZ 4) DR. JEFF PAVELL For 2. To ratify the appointment of Salberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3 . To approve an amendment to the Company’s Articles of Incorporation to e f fect a reverse stock split of the Company’s outstanding common stock, at a ratio within the range of 1 - for - 2 to 1 - for - 20 , with the final ratio to be selected by our board of directors in its discretion at any time, if at all, within one year of the date of the 2025 Annual Meeting without further approval or authorization of our stockholders . For 4. To approve the First Amendment to the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan. For 5 . To authorize the adjournment of the 2025 Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the 2025 Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals . NOTE: To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Voting Items Board Recommends

     

    Get the next $SILO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SILO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SILO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exer

    10/1/25 4:20:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that wil

    9/30/25 8:02:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management

    Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\. Eric Weisblum, CEO of Silo, commented, "Fireblocks brings unmatched ex

    9/29/25 2:30:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/28/25 4:30:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/24 5:00:06 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/22/24 4:16:10 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    SEC Filings

    View All

    Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    10/1/25 4:30:26 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 424B5 filed by Silo Pharma Inc.

    424B5 - Silo Pharma, Inc. (0001514183) (Filer)

    10/1/25 8:51:32 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form DEFA14A filed by Silo Pharma Inc.

    DEFA14A - Silo Pharma, Inc. (0001514183) (Filer)

    9/5/25 5:09:03 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/28/25 4:30:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 4 filed by Director Linsley Wayne

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/27/25 7:03:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 4 filed by Director Munoz Kevin

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/27/25 7:03:16 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    7/26/24 4:17:36 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    6/13/24 5:08:53 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

    SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    1/25/24 5:27:04 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary